PTO- 1581 |
Approved for use through 03/31/2024. OMB 0651-0054 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Input Field |
Entered |
SERIAL NUMBER | 88155166 |
---|---|
LAW OFFICE ASSIGNED | LAW OFFICE 104 |
MARK SECTION | |
MARK | UMBRAYA (see, http://uspto.report/TM/88155166/mark.png) |
STANDARD CHARACTERS | YES |
USPTO-GENERATED IMAGE | YES |
LITERAL ELEMENT | UMBRAYA |
OWNER SECTION (current) | |
NAME | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED |
MAILING ADDRESS | CLONSHAUGH BUSINESS and TECHNOLOGY PARK |
CITY | COOLOCK, DUBLIN |
ZIP/POSTAL CODE | D17E400 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | Ireland |
PHONE | 714-246-5351 |
XXXX | |
OWNER SECTION (proposed) | |
NAME | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED |
MAILING ADDRESS | CLONSHAUGH BUSINESS and TECHNOLOGY PARK |
CITY | COOLOCK, DUBLIN |
ZIP/POSTAL CODE | D17E400 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | Ireland |
PHONE | 714-246-5351 |
XXXX | |
ATTORNEY INFORMATION (current) | |
NAME | Matthew O. Brady |
ATTORNEY BAR MEMBERSHIP NUMBER | XXX |
YEAR OF ADMISSION | XXXX |
U.S. STATE/ COMMONWEALTH/ TERRITORY | XX |
INTERNAL ADDRESS | RD3-3B1 |
STREET | 2525 DUPONT DRIVE |
CITY | IRVINE |
STATE | California |
POSTAL CODE | 92612-1531 |
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
PHONE | 714-246-4788 |
FAX | 714-246-4249 |
Matthew.Brady@Allergan.com | |
ATTORNEY INFORMATION (proposed) | |
NAME | Matthew O. Brady |
ATTORNEY BAR MEMBERSHIP NUMBER | XXX |
YEAR OF ADMISSION | XXXX |
U.S. STATE/ COMMONWEALTH/ TERRITORY | XX |
INTERNAL ADDRESS | RD3-3B1 |
STREET | 2525 DUPONT DRIVE |
CITY | IRVINE |
STATE | California |
POSTAL CODE | 92612-1531 |
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
PHONE | 714-246-4788 |
FAX | 714-246-4249 |
mbrady@abbvie.com | |
CORRESPONDENCE INFORMATION (current) | |
NAME | Matthew O. Brady |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | Matthew.Brady@Allergan.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | kent_alexander@allergan.com |
CORRESPONDENCE INFORMATION (proposed) | |
NAME | Matthew O. Brady |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | mbrady@abbvie.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | alexander.kent@abbvie.com |
GOODS AND/OR SERVICES SECTION | |
INTERNATIONAL CLASS | 005 |
CURRENT IDENTIFICATION | Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonia, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhidrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body |
GOODS OR SERVICES | KEEP ALL LISTED |
EXTENSION SECTION | |
EXTENSION NUMBER | 4 |
ONGOING EFFORT | product or service research or development ; market research ; manufacturing activities |
ALLOWANCE MAIL DATE | 04/30/2019 |
STATEMENT OF USE | NO |
PAYMENT SECTION | |
NUMBER OF CLASSES | 1 |
SUBTOTAL AMOUNT [EXTENSION FEE] | 125 |
TOTAL AMOUNT | 125 |
SIGNATURE SECTION | |
SIGNATURE | /mob/ |
SIGNATORY'S NAME | Matthew O. Brady |
SIGNATORY'S POSITION | Attorney of Record |
DATE SIGNED | 03/15/2021 |
SIGNATORY'S PHONE NUMBER | 714-246-4788 |
SIGNATURE METHOD | Signed directly within the form |
FILING INFORMATION | |
SUBMIT DATE | Mon Mar 15 13:52:30 ET 2021 |
TEAS STAMP | USPTO/ESU-XXX.XXX.XXX.XX- 20210315135230795291-8815 5166-7702a4c738ba29f698ff 4d452e7e5dba9c3bdb1278aeb 2f4b85cd2d18a115e4dd-DA-5 2294852-20210315134906441 534 |
PTO- 1581 |
Approved for use through 03/31/2024. OMB 0651-0054 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |